Results 371 to 380 of about 3,106,146 (396)

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Science, 1995
M. Pagano, S. Tam, A. Theodoras, P. Beer-Romero, G. Sal, V. Chau, P. Yew, G. Draetta, M. Rolfe   +8 more
semanticscholar   +1 more source

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly  

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Nature, 2020
Ugur Sahin, Petra Oehm, Mathias Vormehr
exaly  

[Proteasome and proteasome inhibitors].

Annales de dermatologie et de venereologie, 2006
L, Meunier, P-E, Stoebner, M, Marque, L, Henry, J-P, Bureau, T, Lavabre-Bertrand   +5 more
openaire   +1 more source

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

Proteasome Inhibitors

2009
Marie Wehenkel, Yik Khuan Ho, Kyung-Bo Kim   +2 more
openaire   +1 more source

NTRK fusion-positive cancers and TRK inhibitor therapy

Nature Reviews Clinical Oncology, 2018
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon   +2 more
exaly  

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Nature Reviews Clinical Oncology, 2013
Joaquin Mateo, Michael Ong, David S P Tan   +2 more
exaly